SYS-CON MEDIA Authors: Jason Bloomberg, Sandi Mappic, RealWire News Distribution, Kevin Benedict, Bob Gourley

News Feed Item

Harvard Apparatus Regenerative Technology Profiled by MIT Technology Review

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by MIT Technology Review on January 16.

The article, “Manufacturing Organs” highlighted the new focus of Harvard Apparatus Regenerative Technology (HART) post spin-off. It noted the company is stepping up its production of synthetic tracheas to supply clinical trials.

To read the article in its entirety, please visit the following link:

http://www.technologyreview.com/news/522576/manufacturing-organs/

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreathTM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.